J. Goldman & Co’s Cullinan Oncology CGEM Stock Holding History

J. Goldman & Co’s Portfolio CGEM Stock Details CGEM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-42,539	Closed	-$1.77M	–	413
2021 Q1	$1.77M	Buy	+42,539	New	+$1.73M	0.06%	251

Other funds holding CGEM

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Fidelity Investments

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

J. Goldman & Co's CGEM Position: Q2 2021 in Review

J. Goldman & Co sold out of Cullinan Oncology (CGEM) in Q2 2021, closing a stake of 42,539 shares — an estimated $1.77M sold.

J. Goldman & Co first reported a position in CGEM in Q1 2021 and held it in 1 quarter. The position peaked at $1.77M in Q1 2021. 71 funds tracked by Wall St. Rank hold CGEM as of Q2 2021.

J. Goldman & Co reported no remaining Cullinan Oncology position as of Q2 2021 after selling out during the quarter.
J. Goldman & Co sold 42,539 Cullinan Oncology shares in Q2 2021, an estimated $1.77M.
J. Goldman & Co first reported a position in Cullinan Oncology in Q1 2021 and held it in 1 quarter.
J. Goldman & Co's Cullinan Oncology position peaked at $1.77M in Q1 2021.
71 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2021.

Based on J. Goldman & Co's 13F filing for Q2 2021, filed 16 Aug 2021.